Analysts Offer Predictions for ESPR FY2024 Earnings

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Cantor Fitzgerald issued their FY2024 earnings per share (EPS) estimates for Esperion Therapeutics in a report released on Tuesday, December 17th. Cantor Fitzgerald analyst K. Kluska anticipates that the biopharmaceutical company will earn ($0.27) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $8.00 price objective on the stock. The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.27) per share.

Other analysts also recently issued reports about the stock. Needham & Company LLC restated a “buy” rating and set a $6.00 target price on shares of Esperion Therapeutics in a report on Friday, December 13th. HC Wainwright restated a “buy” rating and set a $16.00 price objective on shares of Esperion Therapeutics in a report on Thursday, December 12th. StockNews.com lowered shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Finally, The Goldman Sachs Group assumed coverage on Esperion Therapeutics in a report on Wednesday. They set a “neutral” rating and a $4.00 target price for the company. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $7.30.

Esperion Therapeutics Trading Up 2.8 %

Shares of NASDAQ:ESPR traded up $0.06 during trading on Thursday, hitting $2.22. 680,053 shares of the company’s stock traded hands, compared to its average volume of 6,364,525. The company has a 50-day moving average price of $2.41 and a 200-day moving average price of $2.22. Esperion Therapeutics has a 52 week low of $1.58 and a 52 week high of $3.94. The company has a market cap of $437.42 million, a price-to-earnings ratio of -3.47 and a beta of 1.01.

Institutional Investors Weigh In On Esperion Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BOKF NA acquired a new position in shares of Esperion Therapeutics during the 2nd quarter worth about $26,000. Traphagen Investment Advisors LLC acquired a new position in Esperion Therapeutics during the third quarter valued at approximately $27,000. Xponance Inc. bought a new position in Esperion Therapeutics in the second quarter valued at approximately $28,000. National Bank of Canada FI increased its position in shares of Esperion Therapeutics by 115.9% during the 2nd quarter. National Bank of Canada FI now owns 19,050 shares of the biopharmaceutical company’s stock worth $44,000 after purchasing an additional 10,225 shares during the last quarter. Finally, Sivia Capital Partners LLC bought a new stake in shares of Esperion Therapeutics during the 2nd quarter worth approximately $44,000. 47.39% of the stock is currently owned by institutional investors and hedge funds.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.